Apnimed, Inc. Common Stock (APMD)

PHARMACEUTICAL PREPARATIONS

Apnimed, Inc. Common Stock (APMD) is listed on Nasdaq, where it has traded since July 31, 2026.

Listed On
Nasdaq
Listed Since
July 31, 2026
Market Cap
$704M

About Apnimed, Inc. Common Stock

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Institutional ownership

In 13F filings for the quarter ended September 30, 2026, 39 institutions reported holding APMD, with 15.4 million shares worth $341.0 million in aggregate. The largest reported holder was Alpha Wave Global, with 7.1 million shares worth $154.6 million. Of the 5 largest holders listed below, all 5 opened new positions in APMD during the quarter.

InstitutionSharesValueQuarter change
Alpha Wave Global7,054,954$155MNew position
Tao Capital Management2,178,138$48MNew position
JPMorgan Chase1,438,577$34MNew position
Aberdeen Group945,078$21MNew position
Sectoral Asset Management942,208$21MNew position

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is APMD?

Apnimed, Inc. Common Stock (APMD) is listed on Nasdaq, where it has traded since July 31, 2026.

Who are the largest institutional holders of APMD?

In 13F filings for the quarter ended September 30, 2026, the largest reported holders of APMD were Alpha Wave Global, Tao Capital Management and JPMorgan Chase.

How many institutions own APMD?

39 institutions reported a position in APMD for the quarter ended September 30, 2026, worth $341.0 million in total.

Did institutions buy or sell APMD last quarter?

Of the 5 largest reported holders, all 5 opened new positions in APMD during the quarter. Every reported holder and its change is on the SentiSense ownership page for APMD.

Every reported institutional holder, plus insider and congressional trades in APMD, on SentiSense.